Table 3.
Select reirradiation studies
| Authors | Publication year | N | Primary cancer | Prior RT dose, median, Gy/fx, | Interval to reRT, median, mo | reRT total dose/fx, median | reRT EQD210, median, Gy median | reRT EQD23, median, Gy | Surgery after reRT | Follow-up, median, mo | Local control | Overall survival | Acute or late grade ≥3 toxic effects |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valentini et al2 | 2006 | 59 | Rectum | 50.4/28 | 27 | 40.8/34 | 38.1 | 34.3 | 50.8% | 36 | 1-y 76.3% | 1 y (87.5%) | 5.1%/1.7% |
| Tao et al6 | 2017 | 102 | Rectum | 50.4/28 | 30 | 39/26 | 37.4 | 35.1 | 45% | 28 | 3-y 40% | 3 y (39%) | NR/34% |
| Koroulakis et al10 | 2020 | 28 | Rectum | 54/30 | 48.5 | 44.4/NR | NA | NA | 21.4% | 28.6 | 1-y 66.3% | 1 y (81.8%) | 10.7%/21.4% |
| Lominska et al24 | 2012 | 28 | Pancreas | 50.4/28 | NR | 22.5/3 | 32.8 | 47.3 | 0% | 5.9 | 1-y 85.7% | Median 5.9 mo | 0%/7.1% |
| Dagoglu et al25 | 2016 | 30 | Pancreas | 50.4/28 | 18 | 25/5 | 31.3 | 40 | 0% | 11 | 1-y 78% | 1 y (50%) | 10%/7% |
| Koong et al26 | 2017 | 23 | Pancreas | 50.4/28 | 13 | 25/5 | 31.3 | 40 | 0% | 28 | 1-y 81% | Median 8.5 mo | 8.7%/0% |
| Hunt et al4 | 2018 | 24 | Various | 45/25 | 27.9 | 39/26 | 37.4 | 35.1 | 0% | 16.8 | 1-y 38% | 1 y (50%) | 16.7%/NR |
| Abusaris et al18 | 2012 | 33 | Various | NR | NR | 32/4 | 45.3 | 64 | 0% | 15 | 1-y 64% | 1 y (52%) | 0%/0% |
| Current study | 2021 | 11 | Various | 50/25 | 26.8 | 40/6 | 44.7 | 56.1 | 0% | 14 | 1-y 88.9% | 1 y (70%) | 0%/0% |
Abbreviations: EQD2 = equivalent dose in 2-Gy fractions; fx = fraction; NA = not available; NR = not reported; reRT = reirradiation; RT = radiation therapy.